U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMS control number.

INFORMATION DISCLO	SURE
STATEMENT BY APPL	CANT
(Not for submission under 37 C	FR 1.99)

	Application Number		09026353		
	Filing Date		2001-05-23		
First Named Inventor ARG			ENTA, ET AL.		
	Art Unit		3735		
Examiner Name LACY		LACY	rK, J		
	Attorney Docket Numb	er	0101-P00636US3		

					U.S.	PATENTS			Remove	
Examiner Initial*	Cite No			Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear				
	1									
If you wisl	h to a	 dd additional U.S. Pate	nt citatio	n inform	ation pl	ease click the	Add button.		Add	
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	ition	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1									
If you wisl	h to a	dd additional U.S. Publi	shed Ap	plication	citation	n information p	please click the Ad	d button		
				FOREIG	3N PAT	ENT DOCUM	ENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²			e or	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	ть		
	1									
If you wisl	h to a	l dd additional Foreign P	atent Do	cument	citation	information pl	lease click the Add	button	Add	
			NON	I-PATE	NT LITE	RATURE DO	CUMENTS		Remove	
Examiner Cite Initials* No (blook, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s), publisher, city and/or country where published.							Ţ5			

1		KCI v. BlueSky, Deposition of Penny Campbell with Exhibits dated January 17, 2005	
2		KCI v. BlueSky, Transcript of Deposition of Mark Chariker, M.D., with Exhibits, dated April 5, 2006	
3		KCI v. BlueSky, Transcript of Deposition of Hamlet W. Hopf, M.D., with Exhibits, dated July 4, 2006.	
4		KCI v. BlueSky, Deposition transcript with Exhibits of Thomas K. Hunt dated April 21, 2005.	
5		KCI v. BlueSky, Transcript of Deposition of Donna Goudberg Lockhart, with Exhibits, dated July 7, 2006	
6		KCI v, BlueSky, Transcript of Deposition of Marie Louise Lachule McGregor, dated July 11, 2006.	
7		KCI v. BlueSky, Transcript of Deposition of Michael A. O'Nell, with Exhibits, dated April 6, 2006	
8		KCI v BlueSky, Transcript of Deposition of Vincent B Pizziconi, Ph D , with Exhibits, dated April 7, 2006.	
9		KCI v. BlueSky, Transcript of Deposition of David Turney, with Exhibits, dated June 15, 2006	
1	0	KCI v. BlueSky, Transcript of Deposition of Tianning Xu., with Exhibits, dated April 27, 2006	
1	1	KCl v. BlueSky, Videolaped Deposition of Louis C. Argenta, M.D., with Exhibits, Winston-Salem, North Carolina, Friday, March 17, 2006	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number		09026353
	Filing Date		2001-05-23
	First Named Inventor	ARG	ENTA, ET AL.
	Art Unit		3735
Attorney Docket Number		LACY	rK, J.
		er	0101-P00636US3

12	KCI v_BlueSky, Transcript of Deposition of John T_Goolikasian, Esq., with Exhibits, dated April 19, 2006.	
13	KCl v, BlueSky, Transcript of Deposition of Wilson C. Hayes, Ph.D., with Exhibits, dated March 29, 2006	
14	KCI v. BlueSky, Transcript of Deposition of Cynthia Ann Miller, with Exhibits, dated May 24, 2006	
15	KCl v, BlueSky, Transcript of Deposition of Jeffrey A. Niezgoda, M.D., with Exhibits, dated May 1, 2006	
16	KCI v. BiueSky, Transcript of Deposition of Jeffrey A. Nezgoda, M.D., dated June 8, 2006.	
17	KCl v, BlueSky, Deposition of Orgill with Exhibits dated March 22, 2006	
18	KCl v. BlueSky, Deposition of Donald R. Piper, Jr., dated December 1, 2005.	
19	KCl v, BlueSky, Transcript of Deposition of Kathleen Satterfield, D P M, with Exhibits, dated April 3, 2006	

If you wish to add additional non-patent literature document citation information please click the Add button Add

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

EXAMINER SIGNATURE

Examiner Signature Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GDV or MPEP 901.64. 2 Enter office that issued the document, by the how letter code (WIPO Standard ST3,) 3 For Japanese patent documents, the includation of the vision of the Emperor must precode the serial number of the patent document.

⁴ Nord of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		09026353
Filing Date		2001-05-23
First Named Inventor	ARG	ENTA, ET AL.
Art Unit		3735
Examiner Name	LACY	rk, J.
Attorney Docket Numb	er	0101-P00636US3

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e/1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1,59(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1,579(c).

See attached certification statement.

Niels Haun

- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

Name/Print

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Registration Number

48 488

Signature	/Niels Haun/	Date (YYYY-MM-DD)	2006-10-04

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is not lie and by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C. 12.0 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commence, P. 0. Box 1450, Alexandria, V.3.231-1450, D. ONT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.3.231-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 95.79) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is \$5 U.S. C. 2(b)(2); (2) furnishing of the information solicide that.) (1) the general authority for the collection of this information is used by the U.S. Patient and Trademan Koffice is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested information is used to the patient of t

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S. C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, during an inspection of records conducted by GSA a part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S. C. 294 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing impaction of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the againston pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was fled in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application pare to published application, an application pare to published application and application and applications or an insurance of the published application and applications.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.